8-KFiled Aug 11, 8:00 PM ET
Unicycive Therapeutics Reports Q2 2026 Financial Results
$UNCY · Unicycive Therapeutics, Inc.Research Summary
AI-generated summary of this SEC filing
Unicycive Therapeutics Reports Q2 2026 Financial Results
What Happened
- On August 12, 2026, Unicycive Therapeutics, Inc. (UNCY) announced its financial results for the quarter ended June 30, 2026 and provided a business update. The company furnished a press release with those results as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).
Key Details
- Press release date: August 12, 2026.
- Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
- The press release was furnished as Exhibit 99.1 to the Form 8-K (Item 2.02); the filing also includes the Inline XBRL cover page (Item 9.01).
- This 8-K furnishes the press release (i.e., the release is provided as an exhibit rather than separately filed in a different form).
Why It Matters
- The announcement provides the company’s latest quarterly results and an operational update that investors can use to assess recent performance and near-term prospects.
- Investors should read the furnished press release for specifics on revenue, expenses, cash position, clinical or business milestones and any commentary from management. This Form 8-K does not itself include detailed financial tables beyond the press release exhibit.
- No other material events (such as executive changes, mergers, or bankruptcies) were reported in this filing.